Fig. 2
From: Emerging strategies to target RAS signaling in human cancer therapy
RAS mutational frequency and hotspots in human cancer. A The mutational frequency of KRAS, NRAS, and HRAS in various cancers. B The proportion of RAS mutation hotspots. G12, G13, and Q61 occupy 96–98% of all mutations in KRAS and NRAS isoforms. The data are taken from the Catalogue of Somatic Mutations in Cancer (COSMIC v94). PDAC, pancreatic ductal adenocarcinoma; LUAD, lung adenocarcinoma; CMML, chronic myelomonocytic leukemia; AML, acute myeloid leukemia; LUSC, lung squamous cell carcinoma; CML, chronic myelogenous leukemia; HCC, hepatocellular carcinoma; ccRCC, clear cell renal cell carcinoma